Atlas Trials

Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

Clinical trial NCT07476170 · RECRUITING

Trial details

NCT number
NCT07476170
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Study type
OBSERVATIONAL
HR+/HER2- Advanced or Metastatic Breast Cancer
Start date
2026-03-20
Primary completion
2027-04-01
Enrollment
14000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.